What does this research mean for the field?

Targeted axillary dissection (TAD) removes 15% fewer lymph nodes compared to sentinel lymph node biopsy (SLNB) in breast cancer patients who convert from clinically node-positive to node-negative status after primary systemic treatment. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to compare sentinel lymph node biopsy (SLNB) and targeted axillary dissection (TAD) in breast cancer patients post-primary systemic treatment.

February 19, 2026Clinical Cancer Research

Abstract PS5-08-22: Patients with breast cancer and axillary involvement undergoing Sentinel LYMph Node Biopsy versus Targeted AXillary Dissection after primary systemic treatment: which axillary staging saves more lymphnodes? A registry-based randomized controlled trial (SLYMT-AXSANA EUBREAST 3R)

View Full Paper

Ask AI

Bookmark

The study aims to compare sentinel lymph node biopsy (SLNB) and targeted axillary dissection (TAD) in breast cancer patients post-primary systemic treatment.
Randomized participants with breast cancer undergoing primary systemic treatment to SLNB or TAD.
Inclusion of patients presenting with clinically node-positive status converting to node-negative after treatment.
Prospective data collection using RedCap and assessment of patient-reported outcomes.
Hypothesized 15% lower lymph nodes removed in the TAD group compared to SLNB.
Estimations show approximately 2.72 lymph nodes removed with TAD and 3.2 with SLNB based on preliminary registry data.
Power analysis indicates a need for 340 patients total for robust results.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Registry-based randomized controlled trial compares lymph node removal outcomes in breast cancer patients, suggesting potential benefits.

Cite This Study

Gasparri et al. (2026) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f02e8 https://doi.org/10.1158/1557-3265.sabcs25-ps5-08-22

View Full Paper

Ask AI

Bookmark

Abstract PS5-08-22: Patients with breast cancer and axillary involvement undergoing Sentinel LYMph Node Biopsy versus Targeted AXillary Dissection after primary systemic treatment: which axillary staging saves more lymphnodes? A registry-based randomized controlled trial (SLYMT-AXSANA EUBREAST 3R)

Key Points

Discussion

Implication

Cite This Study

Abstract PS5-08-22: Patients with breast cancer and axillary involvement undergoing Sentinel LYMph Node Biopsy versus Targeted AXillary Dissection after primary systemic treatment: which axillary staging saves more lymphnodes? A registry-based randomized controlled trial (SLYMT-AXSANA EUBREAST 3R)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider